Ex Parte Patent Appeal

An ex parte appeal is the formal process for challenging a patent examiner's final rejection at the Patent Trial and Appeal Board (PTAB). 'Ex parte' means the applicant is on one side and the USPTO (through the examiner) is on the other — there is no opposing party as in inter partes proceedings like IPR. The appeal is available under 35 U.S.C. § 134(a) after the USPTO has issued a final rejection of one or more claims and the applicant disagrees with the examiner's legal or factual grounds. The process begins with a Notice of Appeal, then typically an Appeal Brief (the main written argument), an Examiner's Answer, an optional Reply Brief, and ultimately a decision by a three-judge PTAB panel of Administrative Patent Judges (APJs). The PTAB can affirm the rejection, reverse it (allowing the claims), affirm in part, or introduce a new ground of rejection (rare). If the PTAB affirms, the applicant can further appeal to the U.S. Court of Appeals for the Federal Circuit (35 U.S.C. § 141) or file a civil action in the Eastern District of Virginia (35 U.S.C. § 145). Ex parte appeals are distinct from inter partes proceedings (IPR, PGR, derivation) which involve adverse third parties challenging issued patents or pending applications.

The choice between filing an ex parte appeal and a Request for Continued Examination (RCE) is the most important strategic decision after a final rejection, and it depends on your goals and the nature of the dispute. File an appeal when: (1) The examiner is clearly wrong on the law or facts — e.g., a misapplied claim construction, an incorrect mapping of a prior art reference to a claim, a § 101 analysis that misapplies the Alice/Mayo framework; (2) No claim amendment or new argument would overcome the rejection — the rejection is either legally wrong or based on a reference that simply doesn't teach the claimed feature; (3) You want to build a record for future Federal Circuit or district court proceedings; (4) The patent term considerations favor appeal (appeals generate PTA C-delay credit if won; RCEs pause the B-delay clock). File an RCE when: (1) You are willing to amend claims to overcome the prior art and the scope reduction is acceptable; (2) New prior art search results are available that weren't in the response; (3) The examiner has a plausible interpretation of the references and amendments would help; (4) Time is important — an RCE gets you back in prosecution sooner than waiting 12–36 months for PTAB; (5) A pre-appeal brief conference might resolve the issue (a 5-page informal filing reviewed by a panel before committing to a full appeal). A useful rule: if your best argument is a legal one ('the examiner misapplied the law'), appeal. If your best argument requires a factual adjustment ('amend to add this limitation'), RCE.

Ex parte patent appeals to the PTAB take 12–36 months on average from the date of the Notice of Appeal to a final PTAB decision, though the timeline can vary significantly. As of recent years (2024–2025), the average PTAB ex parte appeal pendency has been approximately 16–24 months. Key milestones: Notice of Appeal filed → Appeal Brief (within 2 months, extendable to 7); Examiner's Answer typically issued 2–6 months after brief; Reply Brief (within 2 months of Answer, extendable to 7); PTAB decision typically 12–24 months after docketing. The PTAB has a backlog of thousands of ex parte appeals — the docketing delay (time from briefing completion to PTAB panel assignment) can be 6–18 months. An oral hearing, if requested, adds 2–6 additional months to the timeline. If the PTAB reverses the rejection, prosecution resumes promptly — the examiner typically issues a notice of allowance within a few months after a PTAB reversal. If the PTAB affirms and you elect to appeal to the Federal Circuit, add another 12–24 months for the full Federal Circuit briefing and decision cycle. PTA (Patent Term Adjustment) accrues during the appeal period: under the C-delay provision of § 154(b), if the applicant wins the appeal (rejection reversed), the entire appeal pendency period counts as C-delay PTA, potentially adding 2–4 years to the patent term. This PTA credit makes appeals particularly attractive for high-value patents where the examiner's position is likely to be overturned.

When the PTAB reverses a rejection, the application is returned to the examiner with an order to issue the patent (assuming no other issues remain pending). Typically, the examiner issues a Notice of Allowance within a few months of the PTAB's reversal decision. The applicant pays the issue fee (approximately $1,200 for small entities, $2,400 for large entities) within 3 months, and the patent issues. Patent Term Adjustment (PTA): if the PTAB reverses the rejection (even in part), the entire pendency of the appeal — from the filing of the Notice of Appeal through the PTAB decision — counts as a C-delay for PTA purposes under 35 U.S.C. § 154(b)(1)(C)(iii). This can add years to the patent term. A reversal after 2 years of appeal pendency = 2 years of additional PTA (which may be partially offset by applicant delays). For blockbuster pharmaceutical and high-value technology patents, a successful PTAB appeal can be extraordinarily valuable — not only are the claims allowed, but the term is extended by the entire appeal pendency. After a PTAB reversal, the applicant can also file continuation applications to pursue additional claim scope, using the parent application's priority date — an important strategy that should be executed before the parent patent issues.

A Pre-Appeal Brief Conference (PABC) is an informal procedure in which a 5-page or shorter written request is filed simultaneously with the Notice of Appeal, asking for a quick panel review of whether the rejection is clearly erroneous. A panel of three examiners (the primary examiner plus two supervisors) reviews the request and reaches one of two outcomes: (1) prosecution is reopened (the rejections are withdrawn or a new office action issues) — no appeal brief needed; or (2) the rejections are maintained and the application proceeds to the formal appeal brief stage. The PABC has no fee and a 5-page limit. It cannot include claim amendments and cannot make new arguments not already in the prosecution history. When to use a PABC: the best candidates are cases where the examiner has made a clear, narrow, reviewable error — for example: the examiner's 102 rejection identifies a reference published after the priority date (a cut-and-dry prior art date error); the examiner's claim construction is explicitly contradicted by clear specification language; the examiner applied a 102 reference to a claim limitation that the reference does not disclose on its face. When not to use a PABC: when the dispute is nuanced and requires a full argument; when you want to defer the appeal period to allow prosecution strategy to develop; when the examiner's position is factually debatable (the panel is unlikely to reverse on a close factual call). The PABC adds no cost and can resolve cases in 3–4 months rather than the 18–24 months of a full appeal — it's almost always worth filing when the error is clear.